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Smmary To improve the efficiency of hepatic intra-arterial (h.i.a.) chemotherapy, we selected pirarubicin
(THP) because it shows good properties for h.i.a. chemotherapy, such as fast and efficient cellular uptake, and
used it for h.i.a. chemotherapy in rabbits with V x 2 tumour implanted in the liver. The anti-tumour effect of
THP upon h.i.a. administration was compared with that upon intravenous (i.v.) injection and also with the
anti-tumour activity of epirubicin (EPI) upon h.i.a. injection using optimal and maximal tolerated doses of
each drug. When tumour growth rates and morphometric examinations were evaluated, it was found that THP
and EPI were effective against V x 2 tumour when injected via the h.i.a. route. The activity of THP was
stronger than that of EPI. As regards h.i.a. injection-related complications, plasma transaminase levels were
temporarily elevated. To demonstrate higher anti-tumour activity and other advantages of h.i.a. injection of
THP. plasma and tumour drug concentrations were determined by high-performance liquid chromatography
after THP or EPI was administered at an equal dose to the rabbit V x 2 model. Hepatic intra-arterial injection
of THP accomplished a selective and higher uptake into the tumour and lower effusion into the plasma than
i.v. injection of THP or h.i.a. injection of EPI. Our findings indicate that THP is the better candidate of the
two drugs tested for the h.i.a. chemotherapy because of its greater anti-tumour activity and the lower systemic
drug exposure achieved upon h.i.a. injection.
Keywords: pirarubicin; hepatic intra-arterial chemotherapy; rabbit V x 2 tumour model; anti-tumour effect;
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Primary hepatocellular carcinoma (HCC) is usually con-
sidered a highly malignant tumour with a prognosis of a few
months' survival from the time of diagnosis (Nagasue et al.,
1984). The best current treatment of HCC is surgical removal
of the primary tumour, but this is successful in only 10-20%
of patients (Okuda et al., 1980, 1985) because of the highly
malignant nature of the tumour and its frequent association
with cirrhosis. Thus, for patients with non-resectable HCC,
hepatic intra-arterial (h.i.a.) chemotherapy has been widely
used in attempts to improve the response rate and the sur-
vival.
The rationale for h.i.a. chemotherapy is based upon the
fact that liver tumours, either primary or metastatic, are
mainly nourished by the hepatic artery (Ackerman, 1972;
Ridge et al., 1987). Hence, chemotherapeutic agents injected
directly into the hepatic artery can be more effective than
those administered by the systemic route by increasing the
exposure of the tumour to a drug.
Among various anti-tumour drugs, doxorubicin (DOX) is
one of the most effective cytotoxic agents in the treatment of
HCC and has also been frequently used in h.i.a. chemo-
therapy. However, h.i.a. chemotherapy with DOX does not
seem to show any clear advantage over systemic administra-
tion because, although the response rate is slightly increased
and the median survival time appears to be somewhat in-
creased no reduction in systemic toxicity is observed when
this route is used (Shah et al., 1977; Bern et al., 1978;
Garnick et al., 1979).
A crucial element in successful h.i.a. chemotherapy is the
use of appropriate drugs. Pirarubicin (THP), a novel DOX
analogue with lower cardiotoxicity, is efficiently metabolised
by the liver in a similar way to other anthracycline agents
and the drug plasma clearance is more than 1.5-fold higher
than that of DOX (Iguchi et al., 1985). Furthermore, the
cellular uptake of THP is faster and more effective than that
of DOX (Kunimoto et al., 1983). Hence, we speculated that
THP is a good candidate for h.i.a. chemotherapy.
In the present study, to prove the hypothesis, we
administered THP by h.i.a. injection at the maximal tolerated
dose (MTD) or the optimal dose (half of MTD) in rabbits
with a V x 2 tumour implanted in the liver. The anti-tumour
activity of THP was then compared with that obtained by
intravenous (i.v.) injection and with that of epirubicin (EPI)
administered by h.i.a. injection, since the clinical evaluation
of EPI through h.i.a. injection has been performed and is
indicated (Pannuti et al.. 1986; Ando, 1987). In the evalua-
tion of anti-tumour activity, morphometric examinations
were performed for quantitative evaluations using a colour
image analyser on tumour cross-sections. We also determined
drug concentrations in the plasma and the tumour after
injection of THP and EPI via the i.v. or h.i.a. route and
assessed the pharmacokinetic advantage of THP injection via
the h.i.a. route.
Materias and methods
Chemicals
Pirarubicin (THP) was provided by Mercian (Tokyo, Japan).
Epirubicin (EPI) was purchased from Kyowa Hakko Kogyo
(Tokyo, Japan). These drugs were dissolved in distilled water
as stock solutions, and they were diluted again by 4.5%
sodium chloride solution (final concentration of0.9% sodium
chloride) to obtain the required concentrations of the drugs
for injection.
Animals
Female Japanese White rabbits weighing 2-3 kg were pur-
chased from Kitayama Labes (Kyoto, Japan). Animals were
housed in individual cages under temperature- and humidity-
controlled conditions; food and water were made available ad
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bits were anaesthetised by intravenous injection of sodium
pentobarbital (35 mg kg-') for all surgical procedures.
V x 2 tumour and tumour implantation
Rabbits with a V x 2 tumour implanted into the hindlimb
were obtained from Funabashi Farm (Chiba, Japan) and the
V x 2 tumour was maintained in our laboratory by succes-
sive transplantation into the liver of rabbits. Viable tumour
tissue taken from the V x 2 tumour was minced into
2 x 2 x 1 mm fragments. Fragments were promptly im-
planted into the subcapsular parenchyma of the left medial
lobe of the liver. When the hepatic mass of the V x 2 tumour
was clearly established, usually 10-14 days after implanta-
tion, the animals were subjected to experimental treatments.
Animal study to evaluate anti-tumour activity
Fourteen days after the implantation, laparotomy was per-
formed on rabbits in each group and the lengths of major
and minor axes of V x 2 tumour grown in an oval shape in
the liver were measured. Following this, THP, EPI or saline
was injected into the periotic vein or the left proper hepatic
artery for 30 s at a volume of I ml kg-' body weight. The
dose levels of the drugs used were established from results of
preliminary toxicity studies in non-tumour-bearing rabbits
that were conducted to determine an appropriate dosage of
each drug. The dose levels used were: 1.1 mg kg-' for THP
and 1.6 mg kg-' for EPI as the optimal doses and
2.2 mg kg-' for THP and 3.1 mg kg-' for EPI as the MTD.
Additionally, 2.2 mg kg-I for EPI was selected to compare its
anti-tumour activity with that of THP at an equal dose.
Seven days after a single injection, lengths of major and
minor axes of V x 2 tumour were measured. All animals
were killed with a lethal intravenous dose of pentobarbital.
Then the liver containing tumour was resected and fixed with
10% buffered formalin solution for pathological and mor-
phometric evaluations. Blood samples were obtained from
the periotic vein before and after the injections of anti-
tumour drugs or saline for measurements of plasma glutamic-
oxaloacetic tansminase (GOT), glutamic-pyruvic trans-
aminase (GPT) and total bilirubin (T-BIL) levels in all rabbits.
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Evaluation ofant-tumour effect
The anti-tmour effect was evaluated by comparing the in-
creases in tumour volumes of different treated groups in 7
days from 14 to 21 days after inoculation and expressed as
the tumour growth profile and the tumour growth rate. The
tumour volume (v) was caculated as
V(mm3) = L x W2/2
where L and W are the major and minor axes (mm) of the
tumour mass.
For pathological examination, liver slices through the
centre of the tumour were stained with haematoxylin and
eosin (H&E) and examined with a microscope. Morphomet-
ric examinations were also performed using a colour image
analyser (Luzexs-III; Nireco, Tokyo, Japan) on the H&E-
stained cross-sections to evaluate quantitatively the histo-
logical-anti-tumour effect. In morphometric evaluations, the
haematoxylin-coloured viable cells were automatically col-
lected from each tumour mass. Then, the ratio of the area of
viable tumour cells to the area of tumour mass was cal-
culated and presented for each group. In addition, three
fields of 400 x magnification were randomly selected from
the outer rim of the tumour in cross-sections after treatment
with THP or EPI at the MTD, and examined for the
measurement of tumour nuclear size (pnm). Tumour nuclear
sizes were measured and input into a colour image analyser,
and the distribution pattern in each group was demonstrated
as the necrotic index.
Measrements ofplawna GOT, GPTand T-BIL levels
Plasma GOT, GPT and T-BIL levels were measured by a
biochemical autoanalyser (Hitachi, 750, Hitachi Koki,
Tokyo, Japan) to evaluate hepatic and biliary toxicities due
to drug exposure.
Animal studyfor determination ofplasma and tissue drug
levels
In a separate experiment, 10 or 11 days after tumour implan-
tation, three rabbits in each group received an i.v. injection
of h.i.a. injection of 2.2 mgkg-' THP or EPI under general
anaesthesia. Blood samples were collec from animals in all
Table I Anti-tumour effects ofpirarubicin andepirubicin administered viaeitheri.v. orh.i.a.injection
against the intrahepatic V x 2 tumour of rabbits
Drug and Dose No. of Tumour vohme Tumourvoloue
treatment (mgkg'} rabbits on day 14 (mm2) onday 21 (mm2) Growth rate
Sham operation - 6 1433 ± 51 a 5542 ± 1674 4.03 ± 0.82
Saline i.v. - 6 1587 + 226 6095 1877 3.78 0.82
Sham operation - 6 1394 518 4386 1314 3.27 0.68
Saline h.i.a. - 5 1808 ± 756 5747 + 1341 3.48 + 1.17
THP i.v. 1.1 5 1577 220 4540 742 2.92 0.57
2.2 4 1415 548 3704 926 2.80 0.75
THP h.i.a. 1.1 5 1730 217 1318 629 0.76 0.39'"'
2.2 5 1811 435 1094±564 0.62±0.28e
EPI i.v. 1.6 5 1999 83 6050 1675 3.06 0.94
2.2 6 1707 708 4076 1736 2.47 0.75
3.1 5 1375 333 4019 1271 2.90 0.43
EPI h.i.a. 1.6 6 1390 329 2256 945 1.77 1.06
2.2 5 1981 641 2457 752 1.28 0.23c
3.1 6 1845 437 2195 668 1.18 0.26c
Growth rate was cakulated as tumour volume on day 21/tmour volume on day 14. The tumour
growthratesinallgroupsgiventhedrugviatheh.i.a. routeweresignificantlylower(P<0.05)thaninthe
saline-treated control group. 'Mean ± s.d. bp<O.05 compared with the i.v. group reiving the same
dose. CP<0.01 compared with the i.v. group receiving the same dose. dp<0.05compared with the ia.
group receiving EPI 1.6mgkg-'. 'P<0.05 compared with the i.a. groups receiving EPI 2.2 and
3.1 mglkg-'.Shdy a. pheci v Lv. and h.. roins dadnd.i
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groups through the femoral vein. Blood was withdrawn into
heparin-coated syringes immediately after drug injection
(within 1 min), and 5, 10, 30, 60 and 120min later. Blood
samples were centrifuged at 3000 r.p.m. for 10 min to obtain
the plasma After the final blood sampling, a portion of the
tumour, and of proximal normal liver tissue (in the tumour-
bearing lobe) and normal liver tissue (in the non-tumour-
bearing right medial lobe) were removed. These samples were
frozen at -20°C until further analyses.
Drug levels determination
The plasma and tissue levels of THP and EPI were deter-
mined using reversed-phase high-performance liquid chrom-
atography (HPLC) as previously reported by Iguchi et al.
(1985). Plasma and tissue samples that had been kept frozen
as described above were thawed and weighed. Each sample
was mixed with 0.1 M ammonia-ammonium chloride buffer
(pH 9.0) and homogenised. The mixture was shaken with
chloroform-methanol mixture (2:1, v/v) to extract THP or
EPI and centrifuged at 3000 r.p.m. for 10 min. The organic
layer was obtained and daunomycin was added as an internal
standard. After the organic solvent was evaporated in vacuo,
the residue was dissolved in water-acetonitrile (1:1, v/v).
The solution was chromatographed in an HPLC system
equipped with fluorescence monitor.
The pharmacokinetic parameters were obtained by com-
puter analysis assuming a trapezoidal and a two-com-
partment open model.
Statistical analysis
Pharmacokinetic results were compared using Student's t-
test. Analyses of data for anti-tumour effects and plasma
GOT levels were done with the Mann-Whitney U-test.
Significance was assumed for the tests at P<0.05.
Resut
Anti-twnour effects ofTHP andEPI on hepatic V x 2 tumour
The anti-tumour effects of THP and EPI administered on
day 14 through the periotic vein or the proper hepatic artery
were evaluated against the established hepatic mass of V x 2
tumour. Tumour volume and the growth rate of the tumour
in each group are shown in Table I. V x 2 tumour in the
non-rug-treated groups, such as those subjected to sham
operation, saline i.v. injection and saline h.i.a. injection, grew
extensively in 7 days after treatments and the growth rates
were consistently about 3.0-4.0 times. Although tumour
Sham operatior
n=6
Saline HIA
n=5
h.i.a.
iv.
Fugwe 1 Photographs of V x 2 tumour in the liver of rabbits
following different treatments. (a) h.i.a. injection of saie. (b)
h.i.a. inj,ecuion of THP. (c) h.i.a. injection of EPI. BarslOO zm.
THP 01.1)
n= 5
THP (2.2)
n= 5
EPI 1.6)
n=6
EPI (2.2)
n= 5
EPi (3.1)
n= 6
THP(1.1)
n = 5
THP (2.2)
n= 4
EPJ (1.6)
n = 5
EPI (2.2)
n=6
EPI (3.1)
n=5
Fugwe 2 Image analysing photographs of viable cell area in the
V x 2 tumour 7 days after treatment.growth was somewhat suppressed in the group that received
i.v. injections of THP or EPI compared with that in the
non-drug-treated groups, the effects were not prominent. On
the other hand, in the group which received h.i.a. THP,
tumour growth was greatly suppressed, the growth rate being
less than 1.0. In other words, these tumours regressed. Re-
markable suppression of tumour growth was also found in
the group that received h.i.a. injections of EPI. The growth
rate, however, was 1.0-2.0 and higher than that observed in
the groups that received h.i.a. THP.
Pathological and morphometric results are shown in
Figures 1 and 2 and Table II. Pathologically, normal-
appearing tumour cells with many mitoses were widely
distributed surrounding the central necrotic parts in the non-
drug-treated groups (Figure la) and in the groups that
received THP or EPI by i.v. injection, and more than 50% of
the tumours consisted of viable tumour cells (shown by black
spots in Figure 2), except in the group given 3.1 mgkg-' EPI
(Figure 2 and Table II). In the group given h.i.a. THP,
necrosis of entire tumours was observed and the necrosis was
massive (Figures lb and 2). Individual cells of the tumour
became pyknotically and necrotically degenerated and hardly
any viable tumour cells were detectable (Table ID). In the
group given h.i.a. EPI, although marked necrosis of the
tumours was observed when compared with the results of the
i.v. injection group, viable tumour cells were still detected to
some extent in the outer rim of the tumour (Figures Ic and 2
and Table II).
The distribution patterns of nuclear sizes in the tumour
treated with the highest dose of THP (2.2mgkg-') or EPI
(3.1 mg kg-1) are shown in Figure 3. Most of the nuclei in
the group given slaine by the i.v. or h.i.a. route were
50-100gm2. The mean sizes of the nuclei in the saline i.v.
and h.i.a. injection groups were 791gi2 (n = 2602) and
83 gim2 (n = 1686) respectively. Although similar patterns
were found in the groups given i.v. injections of THP and
EPI, the ratio of nuclei with larger sizes than 100gLm2 slightly
increased owing to swelling effected by the drugs. The mean
nuclear sizes in the THP and EPI groups were 93 gim2
(n = 1169) and 921g2 (n = 1802) respectively. In the group
given h.i.a. injections of THP, the nuclear size was mostly
smaller than 50gmi' and the mean size was 28gim2
(n = 2786). Nuclear sizes in the group injected with EPI by
the h.i.a. route were also sometimes smaller than 50gm2,
although smaller sizes were not pronounced and large nuclei
were frequently found when compared with those in the THP
group. The mean nuclear size in the group receiving EPI via
h.i.a. injection was 61 gM2 (n = 2434).
Thus, of all the treatments tested, THP administered by
h.i.a. injection showed the strongest anti-tumour activity
against this tumour system.
Hepatic andbiliary toxicity after treatment
Figures 4 and 5 show the plasma GOT and T-BIL levels
before and after each treatment. In some groups given h.i.a.
injections of THP and EPI, plasma GOT levels were tem-
porarily and statistically significantly elevated on day 3 after
injection but fell to levels close to normal levels on day 7.
Plasma GPT levels changed in the same manner as the GOT
levels in these groups (data not shown). No differences were
observed between the THP and EPI groups. Plasma T-BIL
levels did not change appreciably in any of the groups.
Drug levels in plasma and twnour after treatment
Plasma drug levels during a 2 h period after i.v. or h.i.a.
injection of 2.2 mg kg-' THP or EPI are shown in Figure 6.
Plasma levels of THP and EPI after h.i.a. injection were
consistently lower than those after i.v. injection at all times.
The difference in plasma levels after i.v. and h.i.a. injections
was distinctly greater for THP than for EPI. The maximal
concentrations (C..) in plasma accounted for the difference
(Table III). The area under the plasma concentration-time
curve (AUC) for THP injected via the h.i.a. route was 3.3-
Std onparwbcinwith Lv. ad hi.a rois dadndnkstaion
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Tablen Morphometricanalysisoftumourresponses asdeterminedby
imageanalyser on 7daysafter i.v. orh.i.a. administration ofpirarubicin
and epirubicin in rabbits
Drug and Dose No. of Ratio of VTC area
treatment (mgkg-) rabbits K%)
Sham operation - 6 68± 9'
Saline h.i.a. - 5 66 12
THP
i.v. 1.1 5 65 ± 33
2.2 4 51 15
h.i.a. 1.1 5 3 3
2.2 5 0±0
EPI
i.v. 1.6 5 61 ± 19
2.2 6 53±23
3.1 5 30±21 h.i.a. 1.6 6 13 ± 25
2.2 5 25±27
3.1 6 20 17
Ratio of viable tumour cells (VTC) area was calculated as: area of
viable tumour cells/area of tumour mass x 100. aMean ± s.d.
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F-ge 3 Distribution patterns of nuclear size in V x 2 tumours
treated with the highest dose of THP (2.2 mg kg-') and EPI
(3.1 mgkg-'). The analysis was performed using a colour image
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fold smaller than that for THP aiven bx the i.x route.
Similarlv. the AUC of EPI upon h.i.a. injection w-as 2.3-fold
smaller than that upon ix. injection. The plasma AUC and
C__ for THP Miven via h.i.a. injection w-ere remarkabl- low-er
than those of other treatments (Table 111T. The plasma disap-
pearance and tissue transfer of THP and EPI upon h.i.a.
iniection w-ere faster than those upon i.x- injection (Table
111).
Drug levels in V x 2 tumour and normal liver tisse 2 h
after i.x. or h.i.a. iniection of THP or EPI are shou-n in
Table IV. In the tumour the mean level of THP after h.i.a.
iniection w-as about IS-fold higher than that after iLx. injec-
tion. In the case of h.i.a. injection the THP level in the
tumour wxas about 5- and 90-fold higher than that of the
proximal normal lixer tissue and of distal normal rinht lixver
tissue respectivelv. The mean lexel of EPI after h.i.a. injection
was about 25-fold hiTher than that after ix. iniection. though
in one of the three amnmals EPI w-as undetectable. In case of
h.i.a. injection the EPI level in the tumour wxas l1-fold and
3-fold higher than those of proximal normal lix-er tissue and
of distal normal liver tissue.
Discussion
Recentlv. clinical ex-aluations of h.i.a. chemotherap- using
EPI have been performed and show-n the possibility that it
offers pharmacokcinetic and antitumoural potential advan-
tages ox-er DOX iStrocchi et al.. 19S>; Pannuti er ai.. 1986.
Ando. 198T-. According to reports bx Kunimoto et al. (1983t
and b- Iguchi et a!. (19S55. the pharmacokinetic behaxiour of
THP. x-ith its faster cellular uptake and higher plasma
clearance than DOX. indicates that it satisfies basic require-
ments for locoregional chemotherapy. Therefore. w-e antici-
pated that this compound w-ould also be a good candidate
for successful h.i.a. chemotherapx.
In the present study. w-e compared the anti-tumour
actixities and pharmacokinetics of THP and EPI after i.x-. or
h.i.a. injection in the rabbit V x model. This model u-as
selected because of the similan'tv of its xascularisation to
human liver metastases and primar- tumours (Breedis and
Y-ounz. 1954: Miller et al.. 198-s. The anti-tumour actix-ities
of THP and EPI wxere assessed using the optimal and max-
imal tolerated doses as established bx a preliminarx toxicity
studv because wxe thought that the use of reasonable dose
levels in a study. to compare activities w-ould be an important
control point in establishing the practical actixities of the
drugs. At these doses. h.i.a. injection of THP show-ed a
remarkable inhibition of tumour grow-th compared w-ith
other treatment rezimens including h.i.a. inJection of EPI.
and tumour regression w-as achieved.
In the morphometric analysis using a colour image
analvser. the tumours treated w-ith h.i.a. injection of THP
w ere generallv filled w-ith necrotic cells and xiable tumour
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TableIII Pharmacokinetic parameters ofTHPandEPI2 hafteri.v. orh.i.a. administration inrabbitsbearingaV x 2 tumourinthe
liver
Dose cam(aIgnz- t' ALUC2 (ng,h1V}) CF (1h-I1kg) Vd (Ikg-') l@' (h)
Drug (mgkg-') i.v. h.i.a. i.v.,h.i.a. i.v. h.i.a. iv./h.i.a. i.v. h.i.a. i.v. h.i.a. i.v. h.i.a.
THP 2.2 1.32 0.23 5.7 465 142 3.3 9.76 26.04 18.19 49.07 1.32 1.98
EPI 2.2 8.55 2.18 3.9 669 288 2.3 6.47 16.09 24.72 30.37 2.56 1.60
'Maximal concentration. bAea under the curve. 'Plasma clearance. 'Volume of distribution. 'Half-life of the drug.
a
10
b
X 1 i~a
0.1
c
0
0.01
0 30 60 90 120
c
0
E
co
0.1i
0.01,
0 30 60 90 120
Time (min)
Fugwe 6 Plasma concentrations of (a) THP and (b) EPI in
rabbits bearing V x 2 tumours after i.v. (0) and h.i.a. (0)
administration of 2.2 mg kg-'. The data are expressed as means
+ s.d. 'P<0.05 compared with the i.v. group. bP<0.01 com-
pared with the i.v. group.
cells and mitoses were completely absent. Therefore, it might
be impossible for these tumours to regrow. On the other
hand, areas of viable mitotic cells resulting in tumour
regrowth were detectable in the outer rims of tumours treated
with h.i.a. injection of EPI.
The efficacy of h.i.a. chemotherapy has been frequently
limited by drugs' hepatic and biliary toxicity (Hohn et al.,
1986). Plasma GOT and GPT levels, which are considered to
be markers for the disturbance of hepatic cells, were
significantly elevated 3 days after h.i.a. injection with either
of the drugs used and fell to near-baseline levels within 7
days. However, elevation of these markers was not observed
when these drugs were administered by i.v. injection. These
results suggest that THP and EPI were cytotoxic in normal
hepatic cells when they were directly injected via the hepatic
artery but that the disturbances were reversible. Plasma T-
TableIV V x 2tumourand liverlevelsofpirarubicin andepirubicin at
2 h after i.v. or h.i.a. administration in the rabbit model
iLgg tissue (mean ± s.d.)
THP EPI
Organ iv. h.i.a. i.v. h.i.a.
V x 2 tumour
Animal 1 4.47 116.96 2.35 47.58
Animal 2 3.06 57.67 1.95 62.94
Animal 3 8.45 117.19 2.11 ND
5.33 ± 2.80 97.27 ± 34.30a 2.14 ± 0.20 55.26b
P-liver' 5.50± 4.63 21.70± 16.83 1.32 ± 0.36 3.03 ± 1.32a
D-liver" 5.56 5.26 1.09 0.60 1.02 0.26 1.71 ± 1.59
'P<0.05 compared with the i.v. group. bMean value oftwo animals.
'Proximal normal liver tissue to the tumour in the same lobe. dIistal
normal livertissue in non-tumour-bearing right lobe. ND, notdetected.
BIL levels, a marker of biliary toxicity, were not elevated in
any treatments.
The pharmacokinetic data on THP and EPI after i.v. or
h.i.a. injection confirmed the potential advantage of h.i.a.
injection with THP. The h.i.a. injection of THP would result
in a lower exposure of healthy tissues of other organs to the
drug, since the AUC measured in systemic plasma was
markedly reduced following treatment compared with that
upon i.v. injection of the drug. Moreover, h.i.a. injection of
THP achieved higher intratumoral drug concentrations.
When THP was compared with EPI, the intratumoral
accumulation of THP after h.i.a. injection was about 2-fold
higher than that of EPI after the same procedure. The results
of these studies revealed that the increase in tumour THP
concentration after h.i.a. as compared with i.v. injection was
higher than those of other drugs tested, i.e. cisplatin and
doxorubicin, in the rabbit V x 2 model (Khokhar et al.,
1988; Ridge et al., 1988). Furthermore, h.i.a. injection with
THP resulted in selective drug accumulation in the tumour,
since the THP level was about 90-fold higher than that in the
normal liver tissues of non-tumour-bearing lobe. Hepatic
intra-arterial injection of EPI was also observed to result in
selective accumulation, but the selectivity was inferior to that
obtained upon h.i.a. injection of THP.
Our observations in this study clearly demonstrate the
superiority of h.i.a. injection of THP compared with i.v.
injection of THP and h.i.a. injection of EPI with regard to
the therapeutic efficacy and pharmacokinetic behaviour.
Therefore, we believe that THP is a better candidate than
other drugs, including EPI, for h.i.a. chemotherapy in the
treatment of HCC and metastatic liver cancer. Treatment
with THP via h.i.a. injection is now in the late stage of a
phase II study in Japan.
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